|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chuang JC, Neal JW, Niu XM and Wakelee HA:
Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current
data and future prospects. Lung Cancer. 90:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Naidu S and Garofalo M: microRNAs: An
emerging paradigm in lung cancer chemoresistance. Front Med
(Lausanne). 2:772015.PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH: Eastern
Cooperative Oncology Group: Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rose MC, Kostyanovskaya E and Huang RS:
Pharmacogenomics of cisplatin sensitivity in non-small cell lung
cancer. Genomics Proteomics Bioinformatics. 12:198–209. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stinchcombe TE: Recent advances in the
treatment of non-small cell and small cell lung cancer. F1000prime
Rep. 6:1172014. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brabec V and Kasparkova J: Molecular
aspects of resistance to antitumor platinum drugs. Drug Resist
Updat. 5:147–161. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Akiri G, Cherian MM, Vijayakumar S, Liu G,
Bafico A and Aaronson SA: Wnt pathway aberrations including
autocrine Wnt activation occur at high frequency in human
non-small-cell lung carcinoma. Oncogene. 28:2163–2172. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartis D, Csongei V, Weich A, Kiss E,
Barko S, Kovacs T, Avdicevic M, D'Souza VK, Rapp J, Kvell K, et al:
Down-regulation of canonical and up-regulation of non-canonical Wnt
signalling in the carcinogenic process of squamous cell lung
carcinoma. PLoS One. 8:e573932013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stewart DJ: Wnt signaling pathway in
non-small cell lung cancer. J Natl Cancer Inst. 106:djt3562014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakata A, Yoshida R, Yamaguchi R, Yamauchi
M, Tamada Y, Fujita A, Shimamura T, Imoto S, Higuchi T, Nomura M,
et al: Elevated β-catenin pathway as a novel target for patients
with resistance to EGF receptor targeting drugs. Sci Rep.
5:130762015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Connor ML, Xiang D, Shigdar S, Macdonald
J, Li Y, Wang T, Pu C, Wang Z, Qiao L and Duan W: Cancer stem
cells: A contentious hypothesis now moving forward. Cancer Lett.
344:180–187. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen S, Guttridge DC, You Z, Zhang Z,
Fribley A, Mayo MW, Kitajewski J and Wang CY: Wnt-1 signaling
inhibits apoptosis by activating beta-catenin/T cell
factor-mediated transcription. J Cell Biol. 152:87–96. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Teng Y, Wang X, Wang Y and Ma D:
Wnt/beta-catenin signaling regulates cancer stem cells in lung
cancer A549 cells. Biochem Biophys Res Commun. 392:373–379. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Barr MP, Gray SG, Hoffmann AC, Hilger RA,
Thomale J, O'Flaherty JD, Fennell DA, Richard D, O'Leary JJ and
O'Byrne KJ: Generation and characterisation of cisplatin-resistant
non-small cell lung cancer cell lines displaying a stem-like
signature. PLoS One. 8:e541932013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu Y, Li Y, Jun Wei JW and Liu X: The
role of Sox genes in lung morphogenesis and cancer. Int J Mol Sci.
13:15767–15783. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kormish JD, Sinner D and Zorn AM:
Interactions between SOX factors and Wnt/beta-catenin signaling in
development and disease. Dev Dyn. 239:56–68. 2010.PubMed/NCBI
|
|
19
|
Chou YT, Lee CC, Hsiao SH, Lin SE, Lin SC,
Chung CH, Chung CH, Kao YR, Wang YH, Chen CT, et al: The emerging
role of SOX2 in cell proliferation and survival and its crosstalk
with oncogenic signaling in lung cancer. Stem cells. 31:2607–2619.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nakatsugawa M, Takahashi A, Hirohashi Y,
Torigoe T, Inoda S, Murase M, Asanuma H, Tamura Y, Morita R,
Michifuri Y, et al: SOX2 is overexpressed in stem-like cells of
human lung adenocarcinoma and augments the tumorigenicity. Lab
Invest. 91:1796–1804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weina K and Utikal J: SOX2 and cancer:
Current research and its implications in the clinic. Clin Transl
Med. 3:192014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Chen K, Li L, Li R, Zhang J and Ren
W: Overexpression of SOX2 is involved in paclitaxel resistance of
ovarian cancer via the PI3K/Akt pathway. Tumour Biol. 36:9823–9828.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sun FF, Hu YH, Xiong LP, Tu XY, Zhao JH,
Chen SS, Song J and Ye XQ: Enhanced expression of stem cell markers
and drug resistance in sphere-forming non-small cell lung cancer
cells. Int J Clin Exp Pathol. 8:6287–6300. 2015.PubMed/NCBI
|
|
24
|
Tian T, Zhang Y, Wang S, Zhou J and Xu S:
Sox2 enhances the tumorigenicity and chemoresistance of cancer
stem-like cells derived from gastric cancer. J Biomed Res.
26:336–345. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Toschi L, Finocchiaro G, Nguyen TT, Skokan
MC, Giordano L, Gianoncelli L, Perrino M, Siracusano L, Di Tommaso
L, Infante M, et al: Increased SOX2 gene copy number is associated
with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and
predicts improved survival in early stage disease. PloS One.
9:e953032014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Basu-Roy U, Seo E, Ramanathapuram L, Rapp
TB, Perry JA, Orkin SH, Mansukhani A and Basilico C: Sox2 maintains
self renewal of tumor-initiating cells in osteosarcomas. Oncogene.
31:2270–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Y, Shi J, Yang J, Ma Y, Cheng L, Zeng
J, Hao X, Ma C, Wang Y and Liu X: A Wnt/β-catenin negative feedback
loop represses TLR-triggered inflammatory responses in alveolar
epithelial cells. Mol Immunol. 59:128–135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee SH, Oh SY, Do SI, Lee HJ, Kang HJ, Rho
YS, Bae WJ and Lim YC: SOX2 regulates self-renewal and
tumorigenicity of stem-like cells of head and neck squamous cell
carcinoma. Br J Cancer. 111:2122–2130. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Masui S, Nakatake Y, Toyooka Y, Shimosato
D, Yagi R, Takahashi K, Okochi H, Okuda A, Matoba R, Sharov AA, et
al: Pluripotency governed by Sox2 via regulation of Oct3/4
expression in mouse embryonic stem cells. Nat Cell Biol. 9:625–635.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stinchcombe TE, Borghaei H, Barker SS,
Treat JA and Obasaju C: Pemetrexed with platinum combination as a
backbone for targeted therapy in non-small-cell lung cancer. Clin
Lung Cancer. 17:1–9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Galluzzi L, Vitale I, Michels J, Brenner
C, Szabadkai G, Harel-Bellan A, Castedo M and Kroemer G: Systems
biology of cisplatin resistance: Past, present and future. Cell
Death Dis. 5:e12572014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Clevers H and Nusse R: Wnt/β-catenin
signaling and disease. Cell. 149:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tamashiro DA, Alarcón VB and Marikawa Y:
Ectopic expression of mouse Sry interferes with Wnt/beta-catenin
signaling in mouse embryonal carcinoma cell lines. Biochim Biophys
Acta. 1780:1395–1402. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zakaria N, Yusoff NM, Zakaria Z, Lim MN,
Baharuddin PJ, Fakiruddin KS and Yahaya B: Human non-small cell
lung cancer expresses putative cancer stem cell markers and
exhibits the transcriptomic profile of multipotent cells. BMC
cancer. 15:842015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tanaka K, Kumano K and Ueno H:
Intracellular signals of lung cancer cells as possible therapeutic
targets. Cancer Sci. 106:489–496. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Seo E, Basu-Roy U, Zavadil J, Basilico C
and Mansukhani A: Distinct functions of Sox2 control self-renewal
and differentiation in the osteoblast lineage. Mol Cell Biol.
31:4593–4608. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen Y, Shi L, Zhang L, Li R, Liang J, Yu
W, Sun L, Yang X, Wang Y, Zhang Y and Shang Y: The molecular
mechanism governing the oncogenic potential of SOX2 in breast
cancer. J Biol Chem. 283:17969–17978. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen S, Xu Y, Chen Y, Li X, Mou W, Wang L,
Liu Y, Reisfeld RA, Xiang R, Lv D and Li N: SOX2 gene regulates the
transcriptional network of oncogenes and affects tumorigenesis of
human lung cancer cells. PLoS One. 7:e363262012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y,
Liu Y, Lv D, Liu CH, Tan X, et al: SOX2 promotes tumorigenesis and
increases the anti-apoptotic property of human prostate cancer
cell. J Mol Cell Biol. 3:230–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Leis O, Eguiara A, Lopez-Arribillaga E,
Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R
and Martin AG: Sox2 expression in breast tumours and activation in
breast cancer stem cells. Oncogene. 31:1354–1365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xiang R, Liao D, Cheng T, Zhou H, Shi Q,
Chuang TS, Markowitz D, Reisfeld RA and Luo Y: Downregulation of
transcription factor SOX2 in cancer stem cells suppresses growth
and metastasis of lung cancer. Br J Cancer. 104:1410–1417. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen S, Li X, Lu D, Xu Y, Mou W, Wang L,
Chen Y, Liu Y, Li X, Li LY, et al: SOX2 regulates apoptosis through
MAP4K4-survivin signaling pathway in human lung cancer cells.
Carcinogenesis. 35:613–623. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bareiss PM, Paczulla A, Wang H, Schairer
R, Wiehr S, Kohlhofer U, Rothfuss OC, Fischer A, Perner S, Staebler
A, et al: SOX2 expression associates with stem cell state in human
ovarian carcinoma. Cancer Res. 73:5544–5555. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Herreros-Villanueva M, Zhang JS, Koenig A,
Abel EV, Smyrk TC, Bamlet WR, De Narvajas AA, Gomez TS, Simeone DM,
Bujanda L and Billadeau DD: SOX2 promotes dedifferentiation and
imparts stem cell-like features to pancreatic cancer cells.
Oncogenesis. 2:e612013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Oppel F, Müller N, Schackert G, Hendruschk
S, Martin D, Geiger KD and Temme A: SOX2-RNAi attenuates S-phase
entry and induces RhoA-dependent switch to protease-independent
amoeboid migration in human glioma cells. Mol Cancer. 10:1372011.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rybak AP and Tang D: SOX2 plays a critical
role in EGFR-mediated self-renewal of human prostate cancer
stem-like cells. Cell Signal. 25:2734–2742. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Singh S, Trevino J, Bora-Singhal N,
Coppola D, Haura E, Altiok S and Chellappan SP: EGFR/Src/Akt
signaling modulates Sox2 expression and self-renewal of stem-like
side-population cells in non-small cell lung cancer. Mol Cancer.
11:732012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hainaut P and Plymoth A: Targeting the
hallmarks of cancer: Towards a rational approach to next-generation
cancer therapy. Curr Opin Oncol. 25:50–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sun C, Sun L, Li Y, Kang X, Zhang S and
Liu Y: Sox2 expression predicts poor survival of hepatocellular
carcinoma patients and it promotes liver cancer cell invasion by
activating Slug. Med Oncol. 30:5032013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dogan I, Kawabata S, Bergbower E, Gills
JJ, Ekmekci A, W III Wilson, Rudin CM and Dennis PA: SOX2
expression is an early event in a murine model of EGFR mutant lung
cancer and promotes proliferation of a subset of EGFR mutant lung
adenocarcinoma cell lines. Lung cancer. 85:1–6. 2014. View Article : Google Scholar : PubMed/NCBI
|
